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http://dx.doi.org/10.1016/j.asjsur.20Summary Objective: Cholangiocarcinoma is common in Thailand. There are many palliative
treatments available for patients with unresectable tumor, such as endoscopic retrograde cho-
langiopancreatography (ERCP) with stents, percutaneous transhepatic biliary drainage, or sur-
gery. In cases in which ERCP has failed, we propose an alternative technique: the use of
endoscopic ultrasound with fluoroscopy to perform hepaticogastrostomy for palliative drainage
instead of percutaneous transhepatic biliary drainage.
Patients and methods: A case series study was conducted between December 2005 and
December 2009 of 10 patients (4 male and 6 female, average age: 57 years) who presented
with severe jaundice caused by advanced cholangiocarcinoma, who were treated with this pro-
cedure after failure to drain by ERCP. We used an electronic convex curved linear-array fluo-
roscopy-guided echoendoscope to drain the left dilated intrahepatic duct to the stomach by
metallic wallstent. We performed the procedure with the first six patients under general anes-
thesia and with the other four under conscious sedation. Follow-up liver function tests were
done, and clinical symptoms and survival times were recorded.
Results: Hepaticogastrostomy was unsuccessful on the first two patients (success rateZ 8/10;
80%), and effective drainage was obtained in only seven patients. Average total bilirubin
reduction was 14.96 mg/dL (58.75%) and 18.13 mg/dL (71.20%) after 2 weeks and 4 weeks,
respectively, with good quality of life. One patient was not effectively drained because of
malposition of the stent. There were two patients whose stent migrated into the stomach;of Surgery, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok 10400, Thailand.
com (S. Panpimanmas).
n Surgical Association. Published by Elsevier Taiwan LLC. All rights reserved.
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marked dilated bilateral intrahepat
cholangiocarcinoma.one needed a second session with a second wallstent, and the other needed a double pigtail
stent inside the second wallstent. Follow-up survival rates were 32e194 days (average: 123
days).
Conclusion: Endoscopic-ultrasound-guided hepaticogastrostomy is safe and can be a good palli-
ative option for advancedmalignant biliary obstruction because it drains internally and is remote
from the tumor site, promoting a long patency period of prosthesis and better quality of life.
Copyright ª 2013, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Cholangiocarcinoma is a common malignant tumor in the
Thai population, especially in the northeastern part of
Thailand; an area in which liver fluke is endemic. The
curative treatment is surgery, but most patients are inop-
erable by the time they consult a specialist. The choice of
treatment for patients with biliary obstruction caused by
inoperable cancer is controversial. Usually, the first choice
is endoscopic retrograde cholangiopancreatography (ERCP)
with plastic or metallic stents. Another palliative treatment
is percutaneous transhepatic biliary drainage (PTBD),
including external drainage or internal drainage by radio-
logically placing a stent through the tumor into the common
bile duct; however, w28% of these patients have recurrent
obstruction and cholangitis.1 Palliative hepaticoenteric
surgical bypass may offer longer-term patency and better
quality of life compared with PTBD, but the patients will
suffer from postoperative pain, complications and higher
mortality. This proposed technique instead of PTBD, is also
a palliative procedure that drains the biliary duct far from
the site of tumor and avoids open surgery by using an
endoscopic ultrasound (EUS)-guided method to perform
hepaticogastrostomy as a minimally invasive option.2e8
2. Patients and methods
2.1. Patients
A case series study of minimally invasive trial EUS-guided
hepaticogastrostomy was conducted from December 2005 toscan of the liver showed
ic bile duct in type 4 hilarDecember 2009 on 10 patients with indications including
obstructive jaundice from inoperable (advanced) hilar
cholangiocarcinoma with failed ERCP and significant dilation
of the left intrahepatic bile duct (Fig. 1). The exclusion
criteria were shock, coagulopathy, ascites, and non-
cooperation. Four of the patients were male and the other
six were female, and their average age was 57 years. There
were no pathologically proven cases of cholangiocarcinoma.
All patients were diagnosed by clinical findings and imaging.
We performed EUS-guided hepaticogastrostomy using the
technique described below (Figs. 2 and 3); the first six pa-
tients received the procedure under general anesthesia and
the other four under conscious sedation. The patients who
drained successfully had follow-up progression of disease
and blood level of liver function and alkaline phosphatase
were followed 2 and 4 weeks after procedure and data of
survival times were recorded.
2.2. Technique of EUS-guided hepaticogastrostomy
The EUS-guided hepaticogastrostomy technique introduced
by M. Giovannini consists of a two-step procedure which
creates an anastomosis between the dilated left intra-
hepatic bile duct and the stomach.2 He placed a plastic
stent in first step and then replaced it by a covered metallic
stent a few weeks later. In this study, we used the Pentax
EG 38 UT with EUB 6500 Hitachi Ultrasound with convex
curved linear array echo-endoscope and C-arm fluoroscopy.
This technique was applied from technique of EUS-FNA (fine
needle aspiration) by using needle via the EUS endoscope toFigure 2 Endoscopic ultrasound view of needle punctured
through the gastric wall into the dilated left intrahepatic
bile duct.
Figure 3 An 8 Fr 60-mm metallic wallstent in place of hep-
aticogastrostomy with bile flow.
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hepatic duct under general anesthesia or conscious seda-
tion (25 mg pethidine þ 2.5 mg midazolam), the EUS scope
was introduced through the mouth into the stomach.
Through the lesser curvature of the stomach, the dilated
left intrahepatic duct in segment II was identified and
punctured with a 19-gauge EUS needle (WilsoneCook,
Winston-Salem, NC, USA). Under fluoroscopic control, a
contrast agent was injected to show the intrahepatic bile
duct. A guide wire (0.035 inch diameter) was inserted into
bile duct and a cystotome was applied via the scope to
create a tunnel at the lesser curvature of the stomach wall,
then a needle knife was applied via the scope to punctureTable 1 Patient data before and after intervention.
Patient Sex Age
(y)
Hb
(g/dL)
WBC/mL CEA
(ng/mL)
Bismuth
type
Pre
Bilir
(TB/
(mg
1 M 51 9.3 7500 3.15 3A 25.4
2 F 59 10.6 6800 6.22 4 20.5
3 F 44 10.2 10,900 5.38 4 38.3
4 M 48 9.9 9300 7.90 4 22.0
5 F 62 11.5 11,000 3.06 3A 22.6
6 F 56 10.8 5700 12.18 4 17.6
7 M 67 12.6 6300 9.05 4 26.3
8 F 60 10.3 5500 1.96 4 21.8
9 M 58 11.7 8800 3.44 3A 66.2
10 F 65 9.2 17,200 5.38 4 39.6
Average 57 10.6 7800 5.77 25.4
Reduction
of total
bilirubin
AP Z alkaline phosphatase; CEA Z carcinoembryonic antigen; DB
TB Z total bilirubin; WBC Z white blood cell count.the liver into the bile duct by using cauterization. We
preferred a single-step procedure, so instead of placing a
plastic stent to create a fistula, after removing the needle
knife, we placed a 10-mm diameter, 60-mm length covered,
self-expanding metallic stent or wallstent (Boston Scientific
Corporation, Boston, MA, USA) in one step and then
removed the guide wire and EUS scope.3. Results
EUS-guided hepaticogastrostomy was successful in eight of
the 10 patients without any immediate complication such
as massive pneumoperitoneum. Placement of stents was
unsuccessful in the first two patients (success rateZ 8/10;
80%). Effective drainage was obtained in seven patients
while the stent position and drainage in the third patient
was not so effective, because the penetration site of the
stomach was at the esophagogastric junction. Follow-up
observations after 2 weeks and 4 weeks found that average
total bilirubin fell from 25.46 mg/dL to 10.50 mg/dL and
7.33 mg/dL (or reduction rate Z 58.75% and 71.20%),
respectively (Table 1). All successful patients had a good
recovery, and started an oral diet on the day after the
procedure. Follow-up computed tomography (CT) scans
after 2 weeks showed metallic stents, with marked reduc-
tion of dilated intrahepatic bile duct (Fig. 4). There were
two patients whose stents were dislodged and migrated
into the stomach, detected by plain abdominal X-ray on the
day after the procedure; one needed a second session with
a second wallstent and the other required a second wall-
stent and a double pigtail stent placed inside the wallstent
to prevent migration due to the tunnel being too large. Most
of the followed up patients had much improved jaundice
and a good quality of life, and the survival times were-intervention 2 wk post-intervention 4 wk post-
intervention
ubin
DB)
/dL)
AP
(mL)
Bilirubin
(TB/DB)
(mg/dL)
AP
(mL)
Bilirubin
(TB/DB)
(mg/dL)
AP
(mL)
4/20.14 518 27.29/20.29 1269 27.46/18.78 1062
0/17.48 488 3.42/2.16 358 1.25/0.64 615
7/29.45 494 10.42/7.87 501 5.02/3.69 1158
0/16.09 521 12.77/8.80 489 5.20/2.50 720
2/16.78 655 4.22/3.19 218 0.72/0.38 60
0/9.10 823 18.88/13.32 200 14.55/7.10 253
1/18.99 1427 10.07/5.92 716 10.62/7.37 1863
3/16.54 484 18.00/ 14.50 255 8.55/4.92 220
7/40.46 2726 10.50/7.60 7.33/4.53
4/27.49 443 14.96 (58.75%) 18.13 (71.2%)
6/17.49
Z direct bilirubin; F Z female; Hb Z hemoglobin; M Z male;
Figure 4 Follow-up computed tomography scan showed
metallic stent drained at lesser curvature of the stomach and
nearly normal size of the bile duct.
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death were mostly advanced stage of the disease with liver
or multiorgan failure.
4. Discussion
Cholangiocarcinoma is a common malignant tumor of the
bile duct in the Thai population and has the highest
recorded incidence in the world in Northeast Thailand. For
resectable cases, the treatment of choice is surgical
resection but most patients present when the disease is at
an advanced stage or inoperable. There are several options
for treatment, with ERCP and endoprosthesis being the first
choice. If ERCP fails or is not possible, PTBD or endopros-
thesis trans-PTBD are other options but PTBD has a high risk
of infection, obstruction, and subsequent poor quality of
life because the stent is placed across the tumor and theTable 2 Success rate, complications, survival time and
cause of death.
Patient Result of
procedure
Complications Survival
time
Cause of
death
1 Failure e e e
2 Failure e e e
3 Success Cholangitis 1 m 2 d Sepsis
4 Success e 6 m 10 d Sepsis
5 Success Stent migration 7 m 24 d Hepatic
failure
6 Success e 3 m 4 d Hepatic
failure
7 Success e 4 m 10 d Hepatic
failure
8 Success e 1 m 11 d Hepatic
failure
9 Success Stent migration 5 m 2 d Sepsis
10 Success e 5 m 1 d Hepatic
failure
Average 123 d
(4 mo)catheter drains into a bag outside the body. Becker et al
have demonstrated a higher rate of complications in pa-
tients with hilar involvement compared with those without
hilar involvement, with significantly lower stent patency
rates.1
There aremany techniques for draining the biliary duct far
from the tumor site, as described by Soulez et al using fluo-
roscopic, endoscopic and laparoscopic guidance to create a
hepaticogastric anastomosis,9 and Tipaldi using CT guidance
and fluoroscopy with two steps of percutaneous hep-
atogastric drainage.10 Warren indicated that diversion of bile
from the liver into the stomach does not cause gastric ulcers,
which is another advantage of hepaticogastrostomy,11 but
Moss has indicated that gastritis could be a potential
complicationdue to thecontact of gastricmucosawith bile.12
Endoscopic ultrasound, which was developed >20 years
ago, is currently a valuable diagnostic instrument and also a
therapeutic intervention. Since the introduction of the
curved linear array echoendoscope in 1990, many pro-
cedures such as cystogastrostomy for pancreatic pseudo-
cyst, choledochoduodenostomy and hepaticogastrostomy
can be performed by minimally invasive techniques.2e8
EUS-guided hepaticogastrostomy has the same level of
safety as compared with PTBD, but higher effectiveness of
drainage because of the larger diameter of the metallic
stent than the PTBD catheter (10 mm vs. 3 mm).
With our first two patients, in the early stages when we
had no previous experience, we failed to place the stent
because of technical error and we consulted with a radi-
ologist to perform PTBD in both cases. With the third pa-
tient, we succeeded in placing the stent, but the position of
the stent was not favorable because it drained from the left
intrahepaticduct through the esophagogastric junction, so
that it was at the same level as the bile duct and the bile
did not drain well by the natural effect of gravity. However,
the CT scan showed much improvement in the dilated bile
duct after 2 weeks (Fig. 5). With the other patients, with
the benefit of more experience, we placed the stents more
effectively, and bilirubin levels fell rapidly. At the 2-week
follow-up observation, there was significant improvement
in the patients’ bile ducts, and they had a good appetite
and a better quality of life.Figure 5 Follow-up computed tomography scan showed
metallic stent drained at the esophagogastric junction and
much smaller size of the bile duct in the third patient.
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these patients were advanced malignancy, impaired liver
function, off and on cholangitis, bile leakage to the peri-
toneal cavity, stent obstruction or malposition, and poor
drainage of bile. Two patients (Cases 3 and 8) that were not
well drained had survival time of only w1 month because
they quickly developed sepsis and hepatic failure. In other
patients, with rapid reduction of bilirubin, appropriate
positioning of the stent, and very good drainage of bile,
longer survival times were achieved. There were no definite
episodes of bile leakage and stent obstruction.
In conclusion, EUS-guided hepaticogastrostomy can be
done safely, with short hospitalization, and a longer period
of stent patency. It makes the patients more comfortable
and results in a better quality of life. This technique should
be an alternative to PTBD or surgical drainage for patients
with advanced cholangiocarcinoma when palliative ERCP
fails or is not possible.
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